<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952337</url>
  </required_header>
  <id_info>
    <org_study_id>PROVID-CAPNETZ</org_study_id>
    <nct_id>NCT04952337</nct_id>
  </id_info>
  <brief_title>Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)</brief_title>
  <acronym>PROVID-CAPNETZ</acronym>
  <official_title>Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pandemic triggered by the new SARS-CoV-2 presents the German health system with&#xD;
      previously unknown challenges. There are currently no effective therapies for the treatment&#xD;
      of the SARS-CoV-2 lung disease Covid-19.&#xD;
&#xD;
      The aim of the joint project PROVID is to draw conclusions from the often very different&#xD;
      clinical appearance of infections with the SARS-CoV-2 pathogen in order to improve patient&#xD;
      care through targeted clinical management.&#xD;
&#xD;
      The effects of infections with the SARS-CoV-2 pathogen are wide-ranging and include a&#xD;
      spectrum from symptomlessness to infections of the upper respiratory tract, uncomplicated but&#xD;
      also severe pneumonia with lung failure and high mortality.&#xD;
&#xD;
      PROVID will first check whether certain host factors determine the severity and / or the&#xD;
      course of Covid-19. Research is also being carried out into whether the molecular and&#xD;
      clinical values of Covid-19 patients differ from those of patients with pneumonia caused by&#xD;
      other pathogens. In addition, it will be tested whether specific molecular markers describe&#xD;
      the severity of the disease and are suitable as an aid for targeted therapy for Covid-19.&#xD;
&#xD;
      PROVID is an interdisciplinary joint project made up of three sub-projects that are being&#xD;
      implemented at three locations (Charitè-Universitätsmedizin Berlin, Universität Leipzig IMISE&#xD;
      and CAPNETZ STIFTUNG / Hannover).&#xD;
&#xD;
      PROVID is based on three clinical research platforms with a high track record in recruiting&#xD;
      patients with high-quality data and biomaterials on the one hand and guideline-changing&#xD;
      results on the other hand: CAPNETZ (competence network CAP, since 2002, world's largest&#xD;
      database and biobank for CAP), PROGRESS (Pneumonia Research Network on Genetic Resistance and&#xD;
      Susceptibility for the Evolution of Severe Sepsis, since 2007) and CAPSyS (systems medicine&#xD;
      of community-acquired pneumonia, since 2014).&#xD;
&#xD;
      The COVID-19 patients are recruited into 3 different patient cohorts via these 3 research&#xD;
      platforms.&#xD;
&#xD;
      1. PROVID-CAPNETZ, 2. PROVID-PROGRESS, 3. PROVID-CAPSyS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infections with the novel Severe Acute Respiratory Syndrome - Coronavirus-2 (SARS-CoV-2)&#xD;
      manifest with a broad spectrum of clinical presentations, ranging from asymptomatic to upper&#xD;
      respiratory tract infections, uncomplicated pneumonia and severe pneumonia with respiratory&#xD;
      failure and high lethality. Despite more than 1.7 Mio. documented infections worldwide, a&#xD;
      profound lack of knowledge impedes clinical management and the development of therapies.&#xD;
      COVID-19-associated pneumonia and lung injury differ in relevant details from any of the&#xD;
      known types of pneumonia that cause respiratory failure, including viral infections like&#xD;
      influenza or MERS-CoV. Thus, it is unclear whether specific decision guidelines established&#xD;
      for pneumonia are applicable or whether these need to be refined for COVID-19. That is why&#xD;
      the PROVID consortium was founded with BMBF funding. The PROVID consortium thus aims to&#xD;
      characterize the host- and virusdependent mechanisms associated with the clinical appearance&#xD;
      of COVID-19 to improve patient care through advances in risk stratification and clinical&#xD;
      management. Specifically, we aim to test the hypotheses that,&#xD;
&#xD;
        1. host factors (transcriptional response/RNA, proteins, antibodies) determine the severity&#xD;
           and/or course of COVID-19,&#xD;
&#xD;
        2. molecular and clinical determinants of COVID-19 differ from those previously deciphered&#xD;
           in other types of pneumonia and they can be used as molecular predictors for disease&#xD;
           progression,&#xD;
&#xD;
        3. specific molecular markers of severe disease can be tested as therapeutic targets for&#xD;
           COVID-19.&#xD;
&#xD;
        4. In addition to presently pursued antivirals and immunomodulators, the stabilization of&#xD;
           the pulmonary barrier function could establish a third line for an effective therapy.&#xD;
&#xD;
      In PROVID we synergistically combine our expertise in the areas of pneumonia and ARDS,&#xD;
      infection immunology, molecular and medical virology, lung physiology and endothelial cell&#xD;
      biology, experimental lung infection research, statistics and bioinformatics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the host- and virusdependent mechanisms associated with the clinical appearence of COVID-19</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Determination of specific molecular markers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of the course of COVID-19</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Host factors (transcriptional response/RNA, proteins, antibodies) determine the course of COVID-19</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of the severity of COVID-19</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Host factors (transcriptional response/RNA, proteins, antibodies) determine the severity of COVID-19</description>
  </primary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>COVID-19</condition>
  <condition>Viral Pneumonia</condition>
  <condition>Pneumonia Due to Streptococcus Pneumoniae</condition>
  <condition>Bacterial Pneumonia</condition>
  <condition>Pneumonia Due to H. Influenzae</condition>
  <condition>Pneumonia, Organism Unspecified</condition>
  <condition>Pneumonia in Diseases Classified Elsewhere</condition>
  <condition>Pneumonia Due to Other Specified Infectious Organisms</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, urine and materials of the respiratory tracts (upper and lower respiratory tracts)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with positive detection of the SARS-CoV-2 virus (Coronavirus disease-19&#xD;
        (COVID-19))&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  Radiological proof of infiltrate (primarily chest x-ray or CT) with positive detection&#xD;
             of SARS-CoV-2-virus or with no proven infiltrate with positive detection of&#xD;
             SARS-CoV-2-virus&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed, active pulmonary tuberculosis within the last 2 months&#xD;
&#xD;
          -  Simultaneous participation in PROVID-PROGRESS or PROVID-CAPSyS cohort&#xD;
&#xD;
          -  Participation of the patient in PROVID-PROGRESS or PROVID-CAPSyS cohort at an earlier&#xD;
             point in time&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grit Barten-Neiner</last_name>
    <role>Study Director</role>
    <affiliation>CAPNETZ Stiftung</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Grit Barten-Neiner</last_name>
    <phone>+49-(0)511-532-4434</phone>
    <email>office@capnetz.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Krankenhaus Bad Arolsen</name>
      <address>
        <city>Bad Arolsen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Emil von Behring Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carl-Thiem-Klinikum Cottbus</name>
      <address>
        <city>Cottbus</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund gGmbH</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Schaaf, PD Dr.</last_name>
      <phone>+49 (0)231 953-18100</phone>
      <email>bernhard.schaaf@klinikumdo.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik Schillerhöhe</name>
      <address>
        <city>Gerlingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Augustinerinnen</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Agaplesion Diakonieklinikum Rotenburg</name>
      <address>
        <city>Rotenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.gesundheitsforschung-bmbf.de/de/provid-klinische-molekulare-und-funktionelle-biomarker-fur-prognose-pathomechanismen-und-11690.php</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Community-Acquired Pneumonia</keyword>
  <keyword>CAPNETZ STIFTUNG</keyword>
  <keyword>CAP</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumococcal</mesh_term>
    <mesh_term>Pneumonia, Bacterial</mesh_term>
    <mesh_term>Pneumonia, Viral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

